Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/45215
Title: Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up
Authors: Wu, Lihteh
Arevalo, Jose Fernando
Roca, Jose Antonio
Maia, Mauricio [UNIFESP]
Berrocal, Maria Hortensia
Rodriguez, Francisco J.
Evans, Teodoro
Costa, Rogerio Alves [UNIFESP]
Cardillo, José Augusto [UNIFESP]
PACORES
Inst Cirugia Ocular
Clin Oftalmol Ctr
Clin Ricardo Palma
Universidade Federal de São Paulo (UNIFESP)
Univ Puerto Rico
Univ Rosario
Hosp Olhos Araraquara
Keywords: bevacizumab
branch retinal vein occlusion
macular edema
vascular endothelial growth factor
Issue Date: 1-Feb-2008
Publisher: Lippincott Williams & Wilkins
Citation: Retina-the Journal Of Retinal And Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 28, n. 2, p. 212-219, 2008.
Abstract: Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO).Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months.Results: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P < 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT +/- SD decreased from 461 +/- 211 mu m at baseline to 321 +/- 152 mu m at 1 month, 273 +/- 99 mu m at 3 months, and 277 +/- 114 mu m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT +/- SD decreased from 385 +/- 168 mu m at baseline to 279 +/- 111 mu m at 1 month, 249 +/- 97 mu m at 3 months, and 240 +/- 93 mu m at 6 months (P = 0.011).Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition.
URI: http://repositorio.unifesp.br/11600/45215
ISSN: 0275-004X
Other Identifiers: http://dx.doi.org/10.1097/IAE.0b013e3181619bee
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.